Inhibition of the expression of a proliferation-induced ligand APRIL in HepG2 cell line and the reversal on tumor immune evasion by Chinese medicine

Authors

  • Shi-Hai Kan Department of Human Anatomy, Binzhou Medical University, 346 Guanhai Road, Yantai
  • Jing Tang Department of Laboratory Medicine, Yantai Economic and Techno-logical Development Zone Hospital, Yantai
  • Du-Jun Li Department of Laboratory Medicine, Yantai Economic and Techno-logical Development Zone Hospital, Yantai
  • Zhi-Qiang Wang Department of Human Anatomy, Binzhou Medical University, 346 Guanhai Road, Yantai
  • Chun-Xia Li Department of immunology, Jining Medical University, Jining
  • Fei Huang Department of Human Anatomy, Binzhou Medical University, 346 Guanhai Road, Yantai,

DOI:

https://doi.org/10.3329/bjp.v7i4.11888

Keywords:

ADM, Baicali, Cell proliferation, Icarrin, Tumor, Tumor immune evasion

Abstract

This study was designed to examine the role and mechanism of ICA, Baicali in combination with ADM on inhibiting the expression of APRIL in HepG2 cells. MTT assay was used to explore tumor cells proliferation and cytotoxic activity. RT-PCR was used to examine the expression level of APRIL, its receptor HSPG and apoptosis-associated gene bcl-2. ICA, Baicali and ADM can significantly inhibit the proliferation activity of HepG2 cells in a time-dependent manner, and this inhibition of cell proliferation was time dependent; APRIL and its receptor HSPG were strongly expressed on HepG2 cells. In conclusion, by inhibiting the expression of bcl-2 on HepG2 cells, ICA, Baicali and ADM could significantly enhance the susceptibility of HepG2 cells to lysis by CD3AK , reverse tumor immune evasion.

Downloads

Download data is not yet available.
Abstract
621
Download
69 Read
1

References

Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Straten PT. Immunogenicity of Bcl-2 in patients with cancer. Blood 2005; 105: 728-34.

Chen BA, Chen SN, Li CP, Xia S, Jin BC, Wang J, Shao ZY, Gao C, Ding JH, Sun YY. Effect of autologous or allogeneic anti-CD3 monoclonal antibody activated Killer Cells on normal hematopoietic cells. Zhongguo shi yan xue ye xue za zhi 2001; 9: 338-42.

Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998; 188: 1185-90.

Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006; 118: 281-92.

Jang YS, Kim JH, Seo GY, Kim PH. TGF-beta1 stimulates mouse macrophages to express APRIL through Smad and p38MAPK/CREB pathways. Mol Cell. 2011; 32: 251-55.

Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679-88.

Kumar R, Xi Y. MicroRNA, epigenetic machinery and lung cancer. Thoracic Cancer. 2011; 2: 35-44.

Li X, Wainscott C, Xi Y. MicroRNA provides insight into understanding esophageal cancer. Thoracic Cancer. 2011; 2: 134-42.

Liang Y, Fu D, Hu G. Metadherin: An emerging key regulator of the malignant progression of multiple cancers. Thoracic Cancer. 2011; 2: 143-48.

Maniwa Y, Nishio W, Yoshimura M. Application of hRad9 in lung cancer treatment as a molecular marker and a molecular target. Thoracic Cancer. 2011; 2: 7-15.

Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, Huard B. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol. 2006; 80: 697-704.

Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood 2004; 103: 689-94.

Nurwidya F, Takahashi F, Takahashi K. Meeting report: Current cancer perspectives from the 9th Annual Meeting of the Japanese Society of Medical Oncology. Thoracic Cancer. 2012; 3: 94-97.

Okano H, Shiraki K, Yamanaka Y, Inoue H, Kawakita T, Saitou Y, Yamaguchi Y, Enokimura N, Ito K, Yamamoto N, Sugimoto K, Murata K, Nakano T. Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J Gastroenterol. 2005; 11: 4650-54.

Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C, Tschopp J. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000; 192: 1677-84.

Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ. 2001; 8: 403-10.

Sadiq A, Mansour KA. Esophageal cancer: Recent advances. Thoracic Cancer. 2011; 2: 75-83.

Sung YK, Hwang SY, Farooq M, Kim JC, Kim MK. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling. Exper Mol Med. 2003; 35: 257-62.

Tecchio C, Nichele I, Mosna F, Zampieri F, Leso A, Al-Khaffaf A, Veneri D, Andreini A, Pizzolo G and Ambrosetti AA proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia. Eur J Haematol. 2011; 87: 228-34.

Wang F, Chen L, Ding W, Wang G, Wu Y, Wang J, Luo L, Cong H, Wang Y, Ju S, Shao J, Wang H. Serum APRIL, a potential tumor marker in pancreatic cancer. Clin Chem Laboratory Med. 2011; 49: 1715-19.

Xu Y, Liu H, Chen J, Zhou Q. Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009. Thoracic Cancer. 2010; 1: 83-86.

Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nature Immunol. 2000; 1: 252-56.

Zhang JC, Wang ZR, Cheng YJ, Yang DZ, Shi JS, Liang AL, Liu NN, Wang XM. Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D. World J Gastroenterol. 2003; 9: 1482-86.

Downloads

Additional Files

Published

2012-10-15

How to Cite

Kan, S.-H., J. Tang, D.-J. Li, Z.-Q. Wang, C.-X. Li, and F. Huang. “Inhibition of the Expression of a Proliferation-Induced Ligand APRIL in HepG2 Cell Line and the Reversal on Tumor Immune Evasion by Chinese Medicine”. Bangladesh Journal of Pharmacology, vol. 7, no. 4, Oct. 2012, pp. 236-42, doi:10.3329/bjp.v7i4.11888.

Issue

Vol. 7 No. 4 (2012)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).